Quick Answer
Milestone Pharmaceuticals Inc. reported Stockholders Equity of $41.77 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +217.7% in Stockholders Equity from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $73.33 million | Q2 2019: $145.31 million | Q3 2019: $132.83 million | Q1 2020: $99.63 million | Q2 2020: $88.02 million | Q3 2020: $102.20 million | Q1 2021: $131.99 million | Q2 2021: $139.59 million | Q3 2021: $127.42 million | Q1 2022: $100.76 million | Q2 2022: $86.66 million | Q3 2022: $77.16 million | Q1 2023: $53.94 million | Q2 2023: $40.41 million | Q3 2023: $28.50 million | Q1 2024: $39.92 million | Q2 2024: $31.98 million | Q3 2024: $24.01 million | Q1 2025: -$6.12 million | Q2 2025: -$17.75 million | Q3 2025: $20.50 million.
- Over the full 9 years of available data (2017 to 2025), Milestone Pharmaceuticals Inc.'s Stockholders Equity has grown by 60.7%.
- Historical annual values: Fiscal year 2025: $41.77 million | Fiscal year 2024: $13.15 million | Fiscal year 2023: $16.77 million | Fiscal year 2022: $66.35 million | Fiscal year 2021: $112.60 million | Fiscal year 2020: $143.12 million | Fiscal year 2019: $114.92 million | Fiscal year 2018: $83.55 million | Fiscal year 2017: $25.99 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: